Publications

Latest publication 02/15/2021

Transient prenatal ruxolitinib treatment suppresses astrogenesis during developm

Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency...

Array
(
    [id_prestablog_news] => 1383
    [id_shop] => 1
    [date] => 2021-02-15 00:00:00
    [date_modification] => 2024-02-09 14:15:12
    [langues] => ["1","2"]
    [actif] => 1
    [slide] => 0
    [url_redirect] => 
    [average_rating] => 
    [number_rating] => 
    [author_id] => 1
    [featured] => 0
    [ishero] => 0
    [prim_key] => 2951
    [id_lang] => 1
    [title] => Transient prenatal ruxolitinib treatment suppresses astrogenesis during developm
    [paragraph] => Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice
    [content] => 
Authors
L Han-Chung, H Hamizun, MPY Leong

 Lab
Department of Biomedical Sciences, Universiti Putra Malaysia, 43400 UPM, Serdang, Selangor, Malaysia.
Journal
Scientific Reports
Abstract
Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway, which is critical in regulating the gliogenesis process during nervous system development. In the study, we assessed the effect of non-maternal toxic dosages of ruxolitinib (0-30 mg/kg/day between E7.5-E20.5) on the brain of the developing mouse embryos. While the pregnant mice did not show any apparent adverse effects, the Gfap protein marker for glial cells and S100beta mRNA marker for astrocytes were reduced in the postnatal day (P) 1.5 pups' brains. Gfap expression and Gfap+ cells were also suppressed in the differentiating neurospheres culture treated with ruxolitinib. Compared to the control group, adult mice treated with ruxolitinib prenatally showed no changes in motor coordination, locomotor function, and recognition memory. However, increased explorative behaviour within an open field and improved spatial learning and long-term memory retention were observed in the treated group. We demonstrated transplacental effects of ruxolitinib on astrogenesis, suggesting the potential use of ruxolitinib to revert pathological conditions caused by gliogenic-shift in early brain development such as Down and Noonan syndromes.
BIOSEB Instruments Used
Grip strength test (BIO-GS3)

Keywords/Topics
Cancer
    [meta_description] => 
    [meta_keywords] => https://pubmed.ncbi.nlm.nih.gov/33589712/
    [meta_title] => 
    [link_rewrite] => transient-prenatal-ruxolitinib-treatment-suppresses-astrogenesis-during-development-and-improves-learning-and-memory-in-adult-mice
    [actif_langue] => 1
    [read] => 1142
    [count_comments] => 0
    [id] => 1383
    [categories] => Array
        (
            [90] => Array
                (
                    [id_prestablog_categorie] => 90
                    [title] => Cancer
                    [link_rewrite] => Cancer
                )

            [2] => Array
                (
                    [id_prestablog_categorie] => 2
                    [title] => Publications
                    [link_rewrite] => publications
                )

        )

    [authors] => 
    [paragraph_crop] => Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and [...]
    [link_for_unique] => 1
    [products_liaison] => Array
        (
            [48] => Array
                (
                    [name] => Grip strength test
                    [description_short] => 
An easy way to objectively quantify the muscular strength of mice and rats, and to assess the effect of drugs, toxins, muscular (i.e. myopathy) and neurodegenerative diseases on muscular degeneration. It is widely used in conjunction with the ROTAROD motor coordination test: a normally coordinated rodent will show a decreased latency to fall off the rotating rod if its muscular strength is low. The Grip Strength Test is a must for your research on activity, motor control & coordination, and is particularly well suited for studies on Parkinson's & Huntington's disease.
New features GS4 - 2023: Color display with permanent backlight screen for easier reading, reset by footswitch, Improved battery time, Larger data memory of 500 values, Animal counter, USB port (charging/data transfer)

                    [thumb] => 
                    [img_empty] => /var/www/vhosts/de3310.ispfr.net/bioseb2024/modules/prestablog/views/img/product_link_white.jpg
                    [image_presente] => 1
                    [link] => https://bioseb.com/en/activity-motor-control-coordination/48-grip-strength-test.html
                )

        )

)
1